



LUNGCANCER GOES VIRAL

Reinier Wener

Department of Thoracic Oncology and Pulmonary diseases






Reinier.wener@uza.be



CASUS

- 27 jaar, vrouw
- Noord Afrikaanse origine
- Nooit rookster
- Fors verhoogde ANF titers met gewrichtsklachten aan zowel kleine en grote gewrichten
- Rx/ NSAIDs en PCM





Diagnostiek

- Bronchoscopie: bronchusaspiraats eiwitrijk en celarm
- EBUS: klier 7. Lymfoid weefsel. Geen granulomateuze ontsteking
- Mediastinoscopie: Lymfeklierfragmenten met benigne, reactieve veranderingen. Geen argumenten voor een granulomateus proces. Geen argumenten voor lymfoom of carcinoom




Waarschijnlijkheids/ differentiaal diagnose

1. Sarcoidose
2. Hematologische maligniteit/ Lymfoom
3. Tuberculose
4. Pulmonale maligniteit
5. Zeldzame tumor
6. Alles is mogelijk

re Mediastinoscopie + re EBUS (19G) + bronchoscopie

re Mediastinoscopie + re EBUS (19G) + bronchoscopie




NGS negatief, PD-L1 1-5%

Pulmonary LymphoEpithelioma Like Carcinoom

- Zeer zeldzame variant van een NSCLC. 0,4-0,7%
- Meest beschreven bij Aziatische origine
- Epstein-barr virus gerelateerd. EBV ISH +
- Niet rokers
- Forse lymfocyten infiltratie in tumor
- Meestal slecht gedifferentieerd
- Geen moleculaire targets

Pathogenese





Behandeling

1. Chemotherapie
2. Immunotherapie
3. Combinatietherapie chemoimmunotherapie
4. Radiotherapie
5. Multimodale therapie
6. Alles is mogelijk

Systemtherapie


- Chemotherapie?
- Immunotherapie?



OncoTargets and Therapy 2021:14 1073–1081



PD-L1;



Oncotarget 2015;6:33019-32



Zoek de **vout**

Table 3

Univariate analysis for overall survival in patients with LELC.

Variables	No. of patients	5-year OS	P value
Patient number	66		
Age (year)			
<60	39	87.9%	0.510
≥60	27	76.9%	
Sex			
Male	25	76.3%	0.378
Female	41	87.0%	
Smoking status			
Smoker	8	41.7%	<0.001
Nonsmoker	58	86.9%	
Lymph node metastasis			
Positive	30	74.8%	0.060
Negative	36	89.7%	
Stage			
I	26	100.0%	0.023
II	14	75.0%	
III and IV	26	69.2%	
PD-L1			
Positive	50	85.0%	0.231
Negative	16	76.2%	




Abbreviation: OS, overall survival.



Lung Cancer 2015;88:254-9

Behandeling en beloop

- Chemotherapie: Carboplatin – paclitaxel
- Immunotherapie: Pembrolizumab



EBV viral load

- Hoge load geassocieerd met meer gevorderde ziekte, lymfovasculaire infiltratie, lymfklier
- en afstandsmetastasen









Figure 1
C



No. at risk	EBV DNA < 4000 copies/mL	EBV DNA ≥ 4000 copies/mL
0	93	77
20	83	54
40	60	30
60	8	0
80	0	0

	EBV DNA ≥ 4000 copies/mL	EBV DNA < 4000 copies/mL
Median, months (95%CI)	28.5 (25.4–31.3)	42.4 (39.1–45.5)
HR (95%CI)	3.56 (2.63–4.29)	
P value	< 0.001	



Immunoresistentie

- PIK3CA
- IL-7R amplificatie → suppressie van CD 8+ effector T cellen

Dank voor uw aandacht!

MAAR HOE NU VERDER?

...

